Julio Rosenstock, MD, was the lead author of Phase 2 trial results evaluating orforglipron, an oral GLP-1 receptor agonist, published in Diabetes, Obesity and Metabolism.
The study found that orforglipron doses of 12 mg and higher significantly improved β-cell function and insulin sensitivity in participants with type 2 diabetes (T2D). These results support orforglipron’s potential as a meaningful oral treatment option for people living with T2D.
Congratulations to our Dallas site and the entire research team for their contributions to this important work.
Read the full article: https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.70022
